{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:12:02Z","timestamp":1768288322844,"version":"3.49.0"},"reference-count":77,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Despite advances in targeted cancer therapy, the fluoropyrimidines 5\u2010fluorouracil (5FU) and capecitabine continue to play an important role in oncology. Historically, dosing of these drugs has been based on body surface area. This approach has been demonstrated to be an imprecise way to determine the optimal dose for a patient. Evidence in the literature has demonstrated that precision dosing approaches, such as DPD enzyme activity testing and, in the case of intravenous 5FU, pharmacokinetic\u2010guided dosing, can reduce toxicity and yield better patient outcomes. However, despite the evidence, there has not been uniform adoption of these approaches in the clinical setting. When a drug such as 5FU has been used clinically for many decades, it may be difficult to change clinical practice. With the aim of facilitating change of practice, issues and barriers to implementing precision dosing approaches for 5FU and capecitabine are identified and discussed with possible solutions proposed.<\/jats:p>","DOI":"10.1111\/bcp.14723","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T10:03:24Z","timestamp":1609581804000},"page":"317-325","source":"Crossref","is-referenced-by-count":20,"title":["Overcoming barriers to implementing precision dosing with 5\u2010fluorouracil and capecitabine"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8009","authenticated-orcid":false,"given":"Jennifer J.","family":"Schneider","sequence":"first","affiliation":[{"name":"Discipline of Clinical Pharmacology, School of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Centre for Drug Repurposing and Medicines Research Level 3 Hunter Medical Research Institute  Kookaburra Circuit Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-2529","authenticated-orcid":false,"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[{"name":"Discipline of Clinical Pharmacology, School of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Centre for Drug Repurposing and Medicines Research Level 3 Hunter Medical Research Institute  Kookaburra Circuit Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-0199","authenticated-orcid":false,"given":"Jennifer H.","family":"Martin","sequence":"additional","affiliation":[{"name":"Discipline of Clinical Pharmacology, School of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Centre for Drug Repurposing and Medicines Research Level 3 Hunter Medical Research Institute  Kookaburra Circuit Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"3","key":"e_1_2_9_2_1","first-page":"223","article-title":"A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment","volume":"93","author":"Deac AL","year":"2020","journal-title":"Med Pharm Rep"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.15.163998"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3282f945aa"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3054-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2863"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.4_suppl.579"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp328"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3067"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr277"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2031717"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109352"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01598.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-003-0330-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06907-0"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000238"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13007"},{"issue":"1","key":"e_1_2_9_18_1","first-page":"668","article-title":"Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5\u2010fluorouracil and the clinical outcome following definitive 5\u2010fluorouracil\/cisplatin\u2010based chemoradiotherapy in patients with esophageal squamous cell carcinoma","volume":"17","author":"Kuwahara A","year":"2019","journal-title":"Oncol Lett"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00050.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2019.1665875"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1741"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9289"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0889-1"},{"issue":"1","key":"e_1_2_9_24_1","article-title":"Polymorphisms of MTHFR and TYMS predict capecitabine\u2010induced hand\u2010foot syndrome in patients with metastatic breast cancer","volume":"39","author":"Lin S","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3289"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104594"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.641"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1124"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24338"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.650"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.01.102"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050043"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00002"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01765.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2466-0"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.94"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1105"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000099984"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26595"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181ae4516"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12821"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7155\/3\/4\/047002"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.08.002"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030113"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.02.008"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1559325820951367"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20375"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510258"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.09.028"},{"issue":"2","key":"e_1_2_9_51_1","first-page":"74","article-title":"Upfront DPD deficiency detection to secure 5\u2010FU administration: Part 1 \u2010 Where do we stand?","volume":"4","author":"Launay M","year":"2017","journal-title":"Clin Cancer Drugs"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2174\/2212697X04666170817123425"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0540-0"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.010"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/1559325818803042"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12762"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12877"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200206000-00016"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0357"},{"issue":"4","key":"e_1_2_9_60_1","first-page":"123","article-title":"Improving accuracy of 5\u2010fluorouracil test results by reducing pre\u2010analytical variability","volume":"7","author":"Cook P","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"e_1_2_9_61_1","first-page":"16","article-title":"Microsampling as an alternative collection method to venous blood to quantify capecitabine and its metabolites by LC\u2010MS\/MS","volume":"14","author":"Radovanovic M","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.2741"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.03.002"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3743"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573412912666160811114339"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3679-4"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202120"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmy020"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00569.x"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3679-4"},{"issue":"1","key":"e_1_2_9_71_1","first-page":"20","article-title":"Bridging the gap between theory and practice; the active role of inpatient pharmacists in therapeutic drug monitoring","volume":"7","author":"Alhameed AF","year":"2019","journal-title":"Pharm: J Pharm Educ Pract"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01609"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2014.09.007"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.09.14"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1954"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3722-5"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220904999"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175998"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14723","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:46:00Z","timestamp":1693212360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bcp.14723"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14723","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}